ABVC BioPharma (ABVC) Competitors $3.35 -0.23 (-6.42%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$3.44 +0.09 (+2.66%) As of 05:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVC vs. TRDA, IMMP, FENC, KOD, SOPH, SCPH, EDIT, NMRA, TKNO, and ELDNShould you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include Entrada Therapeutics (TRDA), Prima BioMed (IMMP), Adherex Technologies (FENC), Kodiak Sciences (KOD), SOPHiA GENETICS (SOPH), scPharmaceuticals (SCPH), Editas Medicine (EDIT), Neumora Therapeutics (NMRA), Alpha Teknova (TKNO), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry. ABVC BioPharma vs. Its Competitors Entrada Therapeutics Prima BioMed Adherex Technologies Kodiak Sciences SOPHiA GENETICS scPharmaceuticals Editas Medicine Neumora Therapeutics Alpha Teknova Eledon Pharmaceuticals Entrada Therapeutics (NASDAQ:TRDA) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends. Which has stronger valuation and earnings, TRDA or ABVC? Entrada Therapeutics has higher revenue and earnings than ABVC BioPharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntrada Therapeutics$210.78M1.13$65.63M$0.817.73ABVC BioPharma$510K111.54-$4.90M-$0.13-25.77 Which has more volatility & risk, TRDA or ABVC? Entrada Therapeutics has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Do analysts prefer TRDA or ABVC? Entrada Therapeutics presently has a consensus price target of $25.67, indicating a potential upside of 310.01%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Entrada Therapeutics is more favorable than ABVC BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25ABVC BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals believe in TRDA or ABVC? 86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 7.6% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 17.1% of ABVC BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is TRDA or ABVC more profitable? Entrada Therapeutics has a net margin of 14.39% compared to ABVC BioPharma's net margin of -963.46%. Entrada Therapeutics' return on equity of 5.84% beat ABVC BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Entrada Therapeutics14.39% 5.84% 4.61% ABVC BioPharma -963.46%-29.62%-14.08% Does the media favor TRDA or ABVC? In the previous week, ABVC BioPharma had 3 more articles in the media than Entrada Therapeutics. MarketBeat recorded 3 mentions for ABVC BioPharma and 0 mentions for Entrada Therapeutics. ABVC BioPharma's average media sentiment score of 0.33 beat Entrada Therapeutics' score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the news media. Company Overall Sentiment Entrada Therapeutics Neutral ABVC BioPharma Neutral SummaryEntrada Therapeutics beats ABVC BioPharma on 12 of the 17 factors compared between the two stocks. Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVC vs. The Competition Export to ExcelMetricABVC BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.88M$2.93B$5.51B$9.40BDividend YieldN/A2.48%4.00%4.04%P/E Ratio-25.7719.8828.1919.77Price / Sales111.54229.13417.6388.88Price / CashN/A40.8024.9928.17Price / Book55.837.668.155.69Net Income-$4.90M-$55.16M$3.25B$257.97M7 Day Performance-4.56%1.10%0.42%1.92%1 Month Performance82.07%13.14%7.76%12.82%1 Year Performance305.57%3.51%33.64%19.22% ABVC BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVCABVC BioPharma0.4655 of 5 stars$3.35-6.4%N/A+305.6%$56.88M$510K-25.7730TRDAEntrada Therapeutics2.8968 of 5 stars$6.31-7.2%$25.67+306.8%-63.1%$239.48M$172.22M7.79110IMMPPrima BioMed0.9768 of 5 stars$1.64-3.3%$7.00+328.1%-12.4%$238.78M$5.14M0.002,021Positive NewsFENCAdherex Technologies2.1007 of 5 stars$8.62-2.0%$13.00+50.9%+32.1%$238.05M$47.54M-16.9110KODKodiak Sciences3.7172 of 5 stars$4.51-12.8%$9.00+99.7%+92.3%$237.79MN/A-1.2490High Trading VolumeSOPHSOPHiA GENETICS2.3301 of 5 stars$3.54+2.3%$7.00+97.7%-18.8%$236.07M$67.17M-3.54520SCPHscPharmaceuticals4.3962 of 5 stars$4.43-1.1%$14.00+216.1%+11.8%$233.60M$36.33M-2.3230Positive NewsEDITEditas Medicine4.0321 of 5 stars$2.76-3.3%$4.70+70.6%-44.8%$231.46M$32.31M-0.91230Positive NewsNMRANeumora Therapeutics2.3347 of 5 stars$1.42+11.4%$7.50+430.0%-83.6%$228.88MN/A-0.88108News CoverageGap UpTKNOAlpha Teknova1.9004 of 5 stars$4.27-5.0%$12.00+181.4%+96.8%$228.19M$38.25M-8.90240ELDNEledon Pharmaceuticals2.0341 of 5 stars$3.82-2.3%$9.00+135.6%+37.0%$227.25MN/A-1.8110Gap Up Related Companies and Tools Related Companies Entrada Therapeutics Competitors Prima BioMed Competitors Adherex Technologies Competitors Kodiak Sciences Competitors SOPHiA GENETICS Competitors scPharmaceuticals Competitors Editas Medicine Competitors Neumora Therapeutics Competitors Alpha Teknova Competitors Eledon Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABVC) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABVC Stock Alerts